Small Cell Lung Cancer (SCLC)

Latest News

Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.

High-Dose Radiotherapy Boosts Survival Without Toxicity Increase in LS-SCLC

April 20th 2025

Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC

By Roman Fabbricatore

April 18th 2025

Patient-reported adverse effects associated with tarlatamab appeared to be generally mild in the phase 2 DeLLphi-301 trial.

Tarlatamab Shows QOL, Symptom Benefits in Previously Treated SCLC

By Russ Conroy

April 16th 2025

Tarlatamab Displays Overall Survival Benefit in Relapsed SCLC

By Roman Fabbricatore

April 14th 2025

Real-world data may support a new way to consider follow-up treatment for patients who are elderly with extensive-stage small cell lung cancer.

Chemoimmunotherapy Elicits Survival Benefit in Older ES-SCLC Population

By Russ Conroy

April 10th 2025

Latest CME Events & Activities

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

26th Annual International Lung Cancer Congress®

July 25-26, 2025

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies